Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics.
57 stories
Amazon Connect Health made four patient-access capabilities generally available, works with existing phone systems and now links to Redox's network of more than 12,000 EHR and clinical systems.
Eighty percent of the 472 ACOs in the Medicare Shared Savings Program earned bonuses for 2025, CMS said. Gross savings per beneficiary rose, but Medicare's net share slipped as more ACOs took on two-sided risk.
The San Francisco company added Rounding Assistant and Discharge Readiness to its hospital product and pointed to a customer's case mix index data to make the financial case.
OrbiMed led a $120 million Series B on top of a $53 million Series A co-led by Scion Life Sciences and venBio. Marrow's lead drug, for sickle cell disease and beta thalassemia, is in IND-enabling studies.
Greenoaks and Sequoia Capital co-led the round for the London AI drug designer, with Andreessen Horowitz joining and Alphabet investing again. Isomorphic says the money will help push its first programs toward clinical trials.
A final HIPAA Privacy Rule cuts the time to answer a records request from 30 days to 15, makes portal and personal health app access free, and widens sharing for care coordination. HHS puts first-year costs at $784 million.
CMS extended its nationwide bans on enrolling new Medicare hospices and home health agencies, effective Nov. 12, but dropped the freeze on new locations and branches for operators already enrolled.
The proposed CRUSH rule would codify Medicare Advantage audit extrapolation back to 2018, make plans report suspected fraud, require MA clinicians to enroll in Original Medicare and tighten rules for Marketplace brokers.
OpenAI released computer-use agents that click and type through existing health software where APIs fall short, plus more than 20 new plugins from Availity, Redox, TriZetto, UpToDate and others.
The Leeds-based maker of oral liquid medicines will pay $2.70 a share in cash for the Denver drugmaker behind the depression drug EXXUA and a line of ADHD treatments, a 51.7% premium to Aytu's last close before the deal.
Johnson & Johnson will buy the eye disease biotech for $2.2 billion upfront plus up to about $1.125 billion in milestones, and Blackstone has agreed to pay $750 million toward the Phase 3 program for OLN324.
HealthQuest Capital led the round for the Redwood City company, whose pulsed electric field system is 510(k)-cleared for surgical ablation of soft tissue. Galvanize says more than 4,000 procedures have been performed with it.
Calytrix, founded in 2025 by J.P. Morgan's life sciences venture arm, is developing a preclinical antibody for two rare blood cancers driven by mutant calreticulin. Its shareholders could receive up to $1.5 billion in cash.
The virtual U.S. study gives iPhone users an app that answers health questions with OpenEvidence-generated responses and cited sources, and can draw on HealthKit data if participants opt in.
The two departments began participating in Oracle Health Information Network on Nov. 5, Oracle said, adding nationwide TEFCA connections on top of their existing Joint Health Information Exchange.
Wolters Kluwer Health will pay $40 million upfront for AgileMD, a 23-person San Francisco company that sells clinical pathways and an FDA-cleared deterioration alert, with up to $60 million more tied to performance.
The for-profit hospital operator will pay $47 million in cash for a nonprofit system with about $480 million in annual revenue, and commit $200 million over 10 years. Boone's leaders said staying independent was no longer financially feasible.
The Basel immunology company sold about 10.3 million shares at $17, and Sanofi is buying $50 million more in a side placement. Its lead drug targets TSLP, the same protein as AstraZeneca and Amgen's asthma drug Tezspire.
Under a proposed order, immunohistochemistry tests used to select patients for specific cancer drugs, including HER2 and PD-L1 companion diagnostics, would move from Class III to Class II. New tests would need 510(k) clearance rather than a PMA.
Smart ring maker Oura will pay $625 million in cash for Counsel Health, MedTech Dive reported. Counsel is a physician-supervised AI care platform Oura has partnered with since May, and Oura plans to offer the service inside the Oura app.
The agent platform, in preview, reads Epic and Oracle Health records without writing back and links to eligibility, benefits and drug-pricing tools. Customers can choose models from Google, Anthropic or OpenAI.
The telehealth company lowered its 2026 adjusted EBITDA forecast to $257 million to $277 million, swung to a $33 million net loss and disclosed paid agreements tied to new director Andrew Huberman.
All 50 states received Year 2 Rural Health Transformation awards, from about $142 million for New Jersey to $282 million for Texas. It is the first round in which CMS weighed states' progress on their approved plans.
The five-year AWS Health Impact Initiative will award technology credits to nonprofits, governments, researchers and companies working on care access, women's and children's health and healthy food.
Argenx will pay $550 million in cash upfront and up to $595 million in milestones for the Santa Cruz, Calif., macrocyclic peptide company, in which it already owns a stake.
Humana's individual Medicare Advantage rolls grew to 6.46 million from 5.24 million, but its Insurance segment benefit ratio rose to 93.7% and the unit posted an operating loss. It raised its adjusted 2026 EPS floor to $9.50.
Revenue rose 4% to $174.5 million and beat Doximity's own forecast, but cost of revenue and operating expenses grew much faster, and net income fell to $34.7 million from $62.1 million.
The virtual chronic care company's third-quarter revenue rose 34% to $91.3 million, it earned $6.6 million, and it raised its full-year adjusted EBITDA forecast to $32 million to $34 million.
Traditional 510(k)s took a median 140.5 days and special 510(k)s 30, according to openFDA data. About a third of October's 293 clearances came more than 180 days after FDA received the filing.
Advent Life Sciences and the British Business Bank co-led the oversubscribed Series B for the Cambridge, U.K., company, which has now announced $224 million across two rounds.
Home health agencies get an estimated $415 million more in 2027 despite a second 3% temporary cut, and the same rule lets CMS date enrollment revocations for Medicare providers back to when noncompliance began.
Hospitals and surgery centers get a 2.3% Medicare update for 2027, but CMS will pay for 340B-acquired drugs at ASP minus 28%, cutting first-year drug payments by about $5.45 billion and shifting that sum to non-drug services.
Medicare's final 2027 physician pay rule lowers both conversion factors as a one-year 2.5% increase lapses, while adding a 32% visit add-on for ACO clinicians and delaying a remote monitoring staffing limit to 2029.
FDA's clearance count fell from 318 in September and 303 a year earlier, according to openFDA data. Orthopedic devices led the review panels, and general surgery clearances fell by about a third from October 2025.
CVS Health's insurance segment cut its medical benefit ratio to 91.3% from 92.8% and nearly tripled adjusted operating income, and the company raised its adjusted 2026 EPS guidance to at least $8.20.
Third-quarter revenue of $235 million beat the $223 million to $225 million Hinge Health had forecast in August, and the company lifted full-year revenue guidance to $879 million to $881 million.
GoodRx told investors not to rely on its first- and second-quarter 2026 statements. The correction raises revenue and profit, makes Pharma Direct a bigger share of sales and comes with expected material weaknesses in controls.
The Boston developer of long-acting bispecific antibodies for inflammatory diseases sold 10.6 million shares at the midpoint of its range. Its share count implies a market value of about $815 million at the IPO price.
RadNet will pay $350 million in cash and 5 million shares, plus an earnout of up to $210 million, for Onrad, whose 130-plus contracted radiologists support more than 225 hospital facilities.
Insurance-covered therapy revenue at BetterHelp rose to $32.1 million from $3.7 million, but cash-pay revenue fell by about $58.7 million, and Teladoc's third-quarter revenue slipped 3% to $605.1 million.
The scheduling company will let registered AI agents find providers, check insurance and book visits for patients who consent, and it named Instinct as a partner alongside Google Gemini and Amazon Health AI.
Centene's Marketplace membership fell to 3.4 million from 5.8 million, but the insurer lifted its 2026 adjusted EPS floor by 40 cents to more than $5.20 and said Medicare drove a better-than-expected quarter.
Qiagen's boards will recommend EQT's all-cash offer of €46.50 a share, which values the company at about €10.8 billion, or roughly $12.1 billion, including net debt. Closing is expected in mid-2027.
The guidance, announced in the Federal Register Oct. 21, finalizes a 2023 draft. It covers software that drug sponsors distribute with prescription products and says when they should send FDA what that software displays.
Elevance Health's benefit expense ratio improved to 90.6% in the third quarter, and it now expects 2026 adjusted EPS of at least $29. Medicare Advantage membership fell 15.5% from a year earlier to 1.9 million.
The $20-per-ADS cash offer values Silence's equity at about $1.3 billion and centers on divesiran, an siRNA candidate for the rare blood cancer polycythemia vera. Closing is expected in the first quarter of 2027.
The Fort Wayne, Ind., health system agreed to acquire Ovation Healthcare, a Brentwood, Tenn., shared-services company that works with more than 500 health care organizations. Terms were not disclosed.
The deal adds BioReference's clinical, women's health, urology and corrections testing, more than 80 patient service centers and the 4Kscore prostate test, with up to $150 million more tied to 4Kscore sales.
Steris expects the maker of Pink Pad surgical positioning products to bring in about $245 million in 2026 revenue. It will fund the cash deal mainly with debt, backed by a $2 billion bridge commitment.
UnitedHealth Group's third-quarter medical care ratio fell to 88.4% from 89.9%, and it raised its 2026 adjusted EPS outlook to at least $20.50, even as its Medicare Advantage senior count is down 935,000 since the end of 2025.
The share of Medicare Advantage drug contracts with four or more stars fell to about 37% from 44%, and five-star contracts fell to 15 from 22. But weighted by enrollment, about 71% of members are in four-star-plus contracts.
Existing investor BioStar Capital led the Series D, which MMI says brings its total funding to about $345 million. The company will spend it on U.S. and global sales of its Symani robot and on clinical studies.
The $36.50-a-share cash tender offer gives Viatris two U.S. pain products from a company with about $746 million in trailing revenue. Viatris plans to pay mostly from excess cash and close by year-end.
Nextech Invest and Norwest co-led the Series B for the Watertown, Mass., covalent drug developer. The round brings the equity Matchpoint has disclosed raising to about $250 million, not counting Novartis payments.
Andreessen Horowitz led the Series B, which brings the San Francisco company's funding to $152 million. Former Matrix general partner TJ Parker is now CEO, and Eli Lilly is among the investors.
SOFIE Biosciences runs 15 U.S. manufacturing sites with 21 cyclotrons and already makes GE HealthCare's Flyrcado tracer. GE HealthCare is buying it from Trilantic North America in an all-cash deal.
CDRH's lists name 17 documents, and final guidance on AI-enabled device software is an A-list priority. Comments are due Nov. 30.
The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.